Bibliographic information
GuidelineWHO guidelines for malaria, 13 August 2025
Year of Publication2025
Issuing InstitutionWorld Health Organization
Recommendation
New
Artesunate-pyronaridine (ASPY) is recommended as an artemisinin-based combination therapy option for the treatment of uncomplicated P. falciparum malaria.
Recommended in favor
Strong
Certainty of evidence
Low
Notes and Remarks
Remarks
- ASPY should be avoided by individuals with known liver disease (clinically apparent liver disease) because ASPY is associated with liver transaminitis.
- Pharmacovigilance should be strengthened where ASPY is used for the treatment of malaria.
Practical info As with the deployment of any new malaria treatment, pharmacovigilance and resistance surveillance systems should be strengthened.